Attached Carole Ho - 03 Jan 2024 Form 4 Insider Report for Denali Therapeutics Inc. (DNLI)

Role: Chief Medical Officer
Signature: /s/ Tyler Nielsen, by power of attorney
Issuer symbol: DNLI
Transactions as of: 03 Jan 2024
Net transactions value: $0
Form type: 4
Filing time: 05 Jan 2024, 17:57:06 UTC
Previous filing: 25 Aug 2023
Next filing: 09 Jan 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	DNLI	Common Stock	Award	$0	+53,720	+49%	$0.000000	162,434	03 Jan 2024	Direct	F1, F2
holding	DNLI	Common Stock						183,219	03 Jan 2024	See footnote	F3, F4
holding	DNLI	Common Stock						25,000	03 Jan 2024	See footnote	F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	DNLI	Stock Option (right to buy)	Award	$0	+161,160		$0.000000	161,160	03 Jan 2024	Common Stock	161,160	$20.33	Direct	F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each share is represented by a Restricted Stock Unit ("RSU") and a contingent right to receive one share of common stock of the Issuer. 25% of the RSUs shall vest on January 3, 2025 (the "Vesting Commencement Date") and an additional 25% of the RSUs shall vest on each annual anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date.
F2	Includes 136,904 RSU's as of January 4, 2024.
F3	Includes 410 ESPP shares previously held as Direct.
F4	The shares are held of record by the Rohatgi-Ho Family 2009 Revocable Trust, for which Reporting Person serves as trustee.
F5	The shares are held of record by the Rohatgi-Ho Irrevocable GST Trust for the benefit of the Reporting Person's children.
F6	25% of the shares subject to the option shall vest on January 3, 2025, and 1/48 of the shares subject to the option shall vest each month thereafter, subject to the Reporting Person remaining a service provider of the Issuer through each such date.